Survodutide Phase 3 Trial Reveals Baseline Profile of Obesity and Type 2 Diabetes Patients

Obesity and type 2 diabetes (T2D) are global health crises, often co-occurring and significantly increasing the risk of cardiovascular disease, kidney disease, and other serious complications. Current treatments, while effective for some, often fall short for patients with severe disease or multiple comorbidities, highlighting a critical need for more potent and comprehensive therapeutic strategies. This study describes the baseline characteristics of participants in a pivotal Phase 3 trial for survodutide, a novel dual agonist designed to address both conditions.

The analysis of baseline characteristics revealed a patient population with significant metabolic burden, typical for those requiring advanced treatment. The cohort comprised ~1200 participants with a mean age of ~58 years, with ~55% being female. Participants presented with substantial obesity, indicated by a mean baseline BMI of ~35 kg/m² and an average weight of ~105 kg. Their type 2 diabetes was moderately controlled, with a mean HbA1c of ~7.8%. A high prevalence of comorbidities was observed, with ~70% of participants having hypertension and ~60% suffering from dyslipidemia. These characteristics underscore the complexity of the patient population targeted by survodutide. The study describes a patient cohort with severe obesity (mean BMI ~35 kg/m²) and moderately controlled type 2 diabetes (mean HbA1c ~7.8%), alongside a high burden of cardiovascular risk factors.